Law Firm Reminds Aardvark Investors of October 13, 2026 Deadline in Securities Class Action
Faruqi & Faruqi, LLP is investigating potential claims against Aardvark Therapeutics, Inc. and reminds investors of the October 13, 2026 deadline to seek lead plaintiff status in a federal securities class action lawsuit.
New York – September 28, 2026 – Faruqi & Faruqi, LLP, a national securities law firm, is investigating potential claims against Aardvark Therapeutics, Inc. (NASDAQ: AARD). The firm is reminding investors that October 13, 2026, is the deadline to file for lead plaintiff status in a federal securities class action lawsuit filed against the company.
The lawsuit alleges that Aardvark Therapeutics and its executives violated federal securities laws by making false or misleading statements and failing to disclose that offering documents related to the company's initial public offering (IPO) were negligently prepared. The complaint further contends that company executives made materially false and misleading statements regarding the company's business, operations, and prospects throughout the class period.
Specifically, the lawsuit claims that the company's drug candidate ARD-101 was less safe than defendants had led investors to believe. Consequently, ARD-101's clinical, regulatory, and commercial prospects were overstated, leading to materially false and misleading public statements by the defendants.
Aardvark Therapeutics conducted its IPO in February 2025, issuing shares at $16.00 each. On February 27, 2026, the company announced a voluntary pause of its HERO clinical trial due to reported reversible cardiac observations. Following this announcement, the company's stock price experienced a significant decline. In May 2026, the U.S. Food and Drug Administration (FDA) placed a full clinical hold on studies involving ARD-101.